帕尼培南-倍他米隆在血液科病人合并感染中的应用  

Panipenem/betamipron in treating complicated infection of patients in hematologic department

在线阅读下载全文

作  者:魏征[1] 徐建民[1] 邹善华[1] 程志祥[1] 

机构地区:[1]复旦大学附属中山医院血液科,上海200032

出  处:《中国新药与临床杂志》2006年第12期962-964,共3页Chinese Journal of New Drugs and Clinical Remedies

摘  要:目的:观察帕尼培南-倍他米隆在血液科病人合并感染中的治疗效果及安全性。方法:合并感染的血液科病人12例,男性7例,女性5例,年龄(53±s10)a。予帕尼培南-倍他米隆1.0~2.0 g·d-1,静脉滴注,疗程3~10 d。观察临床疗效,随访病原学检查计算清除率,同时在用药前后随访肝、肾功能等评价安全性。结果:致病菌主要包括凝固酶阴性葡萄球菌、肠杆菌、肠球菌以及肺炎克雷伯菌等。治疗有效率为75%,细菌清除率为86%。治疗中未见明显不良反应。结论:帕尼培南-倍他米隆治疗血液科病人合并感染有效且安全。AIM : To evaluate the efficacy and safety of panipenem/betamipron in treating complicated infection of patients in hematologic department. METHODS: Twelve patients (M 7, F 5, age (53 ± s 10) a) with complicated infections in hematologic department were treated with panipenem/betamipron, 1.0 - 2.0 g·d^-1, iv, gtt, individually for a course of 3 to 10 d. The clinical observation, follow-up pathogenesis testing clearance rate together with hepatic and renal function changes were performed before an after the treatment to assess the efficacy and saffety. RESULTS: Pathogens including coagulase-negative Staphylococcus, Streptococcus viridans, Bacillus coli, Enterococcus and Klebsiella were isolated and confirmed with overall efficacy rate 75 % and the bacteria elimination rate 86 %. No serious adverse reactions occurred during the period of treatment. CONCLUSION: Panipenem/betamipron is efficacious and safe in treating complicated infection for patients in hematologic department.

关 键 词:感染 血液病 帕尼培南 倍他米隆 

分 类 号:R978[医药卫生—药品]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象